DBV Technologies, a clinical-stage biopharmaceutical company, announced an aggregate $194 million private investment in public equity financing from the sale of 32,855,669 ordinary shares, as well as pre-funded warrants to purchase up to 28,276,331 ordinary shares.
June 9, 2022
· 6 min read